Pipeline
DTI-301 is a drug candidate under development for inducing on-demand defecation. It is an FDA-approved drug that is administered as a rectal suppository and initiates a rapid contraction of the colorectum to produce defecation. This local mechanism of action allows for lower doses to be used, reduced systemic exposure, and rapid, transient voiding.
DTI-117 is a novel drug candidate under development for inducing on-demand defecation and urination. It is administered as either a sublingual film or intramuscular injection. Rapid, transient voiding of both bowel and bladder contents occurs within minutes of dosing and all effects are terminated within minutes of voiding.